Complex and method for collecting sialic acid
The complex of boronic acid and magnetic particles effectively collects and concentrates sialic acid from biological fluids, addressing the limitations of current cancer detection methods by enabling comprehensive and early-stage cancer detection through selective binding and pH-controlled dissociation, improving cancer testing efficacy.
Patent Information
- Application Number
- PCT/JP2024/011935
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-22
- Filing Date
- 2024-03-26
- Publication Date
- 2024-11-28
AI Technical Summary
Current cancer detection methods, particularly liquid biopsies, face challenges in detecting early-stage cancers due to trace amounts of cancer cells or cancer-derived components in biological fluids and lack comprehensive testing capabilities across different cancer types, making it difficult to effectively identify metastatic cancers.
A complex comprising a boronic acid group with a binding constant of 500M^-1 or more and magnetic particles, specifically designed to selectively bind and concentrate sialic acid in biological fluids, allowing for its collection and enhanced detection through pH-adjusted binding and magnetic separation, followed by dissociation at higher pH for reuse.
This method enables the comprehensive detection of sialic acid, improving cancer testing by concentrating trace amounts and allowing for repeated use of the complex, thereby enhancing the detection of metastatic cancers regardless of cancer type, including early-stage cancers.
Smart Images

Figure JP2024011935_28112024_PF_FP_ABST
Abstract
Description
Complex and method for capturing sialic acid
[0001] The present invention relates to a complex containing a boronic acid group and a magnetic particle, and a method for capturing sialic acid using the complex.
[0002] The cancers suffered by each patient are extremely diverse due to the heterogeneity of cancer tissue. Even in the case of breast cancer, treatment methods are extremely complex, with some cancers being treatable with hormone therapy and others being treatable with molecular targeted drugs. Furthermore, cancer cells that are not effectively treated with hormone therapy or molecular targeted drugs have a high tendency to metastasize, resulting in low survival rates and poor prognosis. Most deaths from cancer are due to metastasis, and early diagnosis of metastatic cancers, especially those with metastatic potential, is essential.
[0003] In recent years, liquid biopsy has been used to detect cancer cells or cancer-derived components shed into biological fluids, such as blood. For example, exosomes secreted by cancer cells contain cancer-specific molecules that are unique to cancer cells. These cancer-specific molecules can be captured and detected by capturing and detecting them in collected biological fluids. Cancer-specific molecules vary depending on the type of cancer. Biomarkers selected for each cancer type, such as epidermal growth factor receptor variant III (EGFRvIII) for glioblastoma and developmentally regulated endothelial cell locus-1 (Del-1) for breast cancer, are typically detected by enzyme-linked immunosorbent assays (ELISAs) utilizing antigen-antibody reactions (see Non-Patent Document 1).
[0004] However, while liquid biopsy is useful for detecting advanced cancers, it cannot be used to detect early-stage cancers, when only trace amounts of cancer cells or cancer-derived components are released into the biological fluid. Furthermore, because the detection is specific to each cancer type using different biomarkers, it is not possible to perform comprehensive cancer testing regardless of cancer type. If comprehensive cancer testing could be realized that targets early-stage cancers and is also applicable to all cancer types, it would greatly enhance the convenience of cancer testing and significantly improve patient prognosis.
[0005] It has long been reported that there is a correlation between sialic acid on cell surface sugar chains and the rate of metastasis (see Non-Patent Document 2). Specifically, sialic acid is overexpressed on the surface of metastatic cancers. The effectiveness of cancer testing that utilizes this characteristic to detect sialic acid has also been reported. Prostate-specific antigen (PSA) is used in cancer testing because it exhibits elevated values in prostate cancer. However, it also exhibits elevated values in benign prostatic hyperplasia and prostatitis, making it a cancer marker that cannot be used to distinguish cancer. In this report, it was reported that 59 of 60 cases in which the PSA test was positive and the cancer / non-cancer status could not be determined were correctly classified as prostate cancer or non-cancer (see Non-Patent Document 3). Thus, the detection of sialic acid has been reported to be effective as a cancer test.
[0006] Regarding the detection of sialic acid, a boronic acid that selectively binds to sialic acid has been reported (see Non-Patent Document 4). In other words, boronic acid selectively interacts with sialic acid from among the various sugars present in the body. Furthermore, although the aminophenylboronic acid used in this report has a low binding affinity to sialic acid, subsequent research has reported boronic acids that have a strong binding affinity to sialic acid (see Non-Patent Document 5). For example, a boronic acid with a pyridine ring skeleton (5-boronopicolinic acid, 5-BPA) has a binding affinity of 1,000 M -1 High binding constant (K a ) has been reported.
[0007] Another achievement of the present inventor (Yukichi Horiguchi) is the report of a cancer detection method that takes into account the properties of sialic acid (see Non-Patent Document 6). This report reports that when gold nanoparticles surface-modified with aminophenylboronic acid are applied to the surface of metastatic cancer cells, the gold nanoparticles gather around the sialic acid expressed on the surface of the cancer cells, resulting in the generation of surface-enhanced Raman scattering that differs from that observed in normal cells. Another achievement of the present inventor (Yukichi Horiguchi) is the detection of the binding state between 5-boronopicolinic acid immobilized on a gold thin film and sialic acid by surface plasmon resonance (SPR) (see Non-Patent Document 7).
[0008] However, previous reports on the detection of sialic acid have problems that make them difficult to apply to cancer testing. Specifically, the biological fluids used in cancer testing contain only trace amounts of sialic acid. Especially in the case of early-stage cancer, the amount of sialic acid in the biological fluid is extremely small, making it difficult to accurately detect sialic acid, and ultimately metastatic cancer. To achieve comprehensive cancer testing that targets early-stage cancer and is applicable to all cancer types, it is necessary to establish a technology that can capture and concentrate sialic acid in biological fluids and improve detection performance.
[0009] Oleoscience Vol. 21 No. 2 (2021) 63 G. Yogeeswaran and P. Salk, Science, 1981, 212, 1514-1516. Y. Haga, M. Uemura, S. Baba, K. Inamura, K. Takeuchi, N. Nomura, K. Ueda, Anal. Chem. 2019, 91, 2247.H. Otsuka, E. Uchimura, H. Koshino, T. Okano, K. Kataoka, J. Am. Chem. Soc. 2003, 125, 3493.A. Matsumoto, AJ Stephenson-Brown, T. Khan, T. Miyazawa, H. Cabral, K. Kataoka, and Y. Miyahara, Chemical Science 8, 6165 (2017).B. Shashni, Y. Horiguchi, K. Kurose, H. Furusho and Y. Nagasaki, Biomaterials, 2017, 134, 143-153. Y. Horiguchi, K. Barthelmes, Y. Miyahara, A. Matsumoto Chemistry Letters, 2021, 50, 1467-1469.
[0010] An object of the present invention is to solve the above-mentioned problems in the prior art and to provide a complex capable of capturing and concentrating sialic acid and a method for capturing the sialic acid.
[0011] The means for solving the above problems are as follows: <1> A complex represented by the following formula (1): B a -L-M p (1) In the formula (1), B a is the binding constant K a is 500M -1 represents the above boronic acid group, and M p represents a magnetic particle having ferromagnetism, L represents a linker that bonds the boronic acid group to the magnetic particle, and the complex represented by formula (1) represents a state in which the boronic acid group and the magnetic particle are chemically bonded via the linker. <2> The complex according to <1>, wherein the magnetic particle is a spherical particle having a diameter of 0.1 μm to 10 μm. <3> The complex according to <1>, wherein the boronic acid group is represented by the following chemical structural formula (B a 1) and (B a The complex according to <1> or <2>, wherein the complex is represented by any one of <1>, <2 ... and <2>. However, the chemical structural formula (B a 1) Medium, R 1 ~R 4 represents a divalent linking group that forms an ester bond, an ether bond, an amide bond, a urethane bond, or a sulfide bond with the linker, and the remaining groups each independently represent a hydrogen atom or an alkyl group having 1 to 2 carbon atoms. a 2) Medium, R 5 ~R 7wherein any one of the groups represents a divalent linking group that forms an ester bond, an ether bond, an amide bond, a urethane bond, or a sulfide bond with the linker, and the remainders independently represent a hydrogen atom or an alkyl group having 1 to 2 carbon atoms. <4> The complex according to any one of <1> to <3>, wherein the linker-forming base material includes an amino group that is surface-modified on the magnetic particle, a thiol compound derivative that is bonded to a boronic acid group, and a link core member that has an amide bond that is amide-bonded to the amino group and a maleimide group that is bonded to the thiol group of the thiol compound derivative. <5> The complex according to <4>, wherein the link core member is a heterobifunctional compound having an N-hydroxysuccinimide ester group and a maleimide group. <6> The complex according to any one of <1> to <5>, wherein the linker has an intermediate moiety that modifies the surface properties of the magnetic particle. <7> The complex according to <6>, wherein the intermediate moiety is composed of a polymer chain of a homopolymer or copolymer of a monomer selected from the group consisting of ethylene glycol, 2-methoxyacrylate, 2-methacryloyloxyethyl phosphorylcholine, and 3-[[2-(methacryloyloxy)ethyl]dimethylammonio]propionate. <8> The complex according to <7>, wherein the polymer chain has a mass-average molecular weight of 2,000 to 10,000. <9> A method for capturing sialic acid, comprising: a binding step of adjusting the pH of a liquid sample containing the complex according to any one of <1> to <8> and a biological fluid containing sialic acid to less than 6, and binding the sialic acid to the complex; a recovery step of separating and recovering the complex from the liquid sample after the binding step using a magnet; and a dissociation step of dissociating the sialic acid from the complex after the recovery step in a concentration solution adjusted to a pH of 7 or higher. <10> The method for capturing sialic acid according to <9>, wherein the complex that has been subjected to the binding step, the recovery step, and the dissociation step is reused to perform the binding step, the recovery step, and the dissociation step on the same or a different biological fluid.
[0012] According to the present invention, the above-mentioned problems in the prior art can be solved, and a complex capable of capturing and concentrating sialic acid and a method for capturing the sialic acid can be provided.
[0013] FIG. 1 is a diagram schematically showing a complex. FIG. 2 is an explanatory diagram showing an outline of a binding step. FIG. 3 is an explanatory diagram showing an outline of a dissociation step. FIG. 4 is a diagram showing a synthesis scheme for a bound compound of boronic acid and a thiol compound derivative. FIG. 5 is a diagram showing a preparation scheme for a complex in which a boronic acid group is complexed with a magnetic particle via a linker. FIG. 6 is a diagram showing the results of a quantitative test of sialic acid. FIG. 7 is a diagram showing the analysis results of the number of sialic acids dissociated in a quantitative test (pH 5.0) and a comparative test (pH 7.6). FIG. 8 is a diagram showing the results of a quantitative test of sialic acid regarding the reuse of a complex. FIG. 9 is a diagram showing the test results of concentration test 1. FIG. 10 is a diagram showing the test results of concentration test 2.
[0014] (Complex) The composite of the present invention is represented by the following formula (1): a -L-M p (1) In the formula (1), B a is the binding constant K a is 500M -1 represents the above boronic acid group, and M p represents a magnetic particle having ferromagnetic properties, L represents a linker that bonds the boronic acid group to the magnetic particle, and the complex represented by formula (1) represents a state in which the boronic acid group and the magnetic particle are chemically bonded via the linker.
[0015] The magnetic particles are arranged for the purpose of recovering the sialic acid bound to the boronic acid group using a magnet. As used herein, the term "ferromagnetic" refers to the property of being attracted to a magnet, and includes ferrimagnetic properties.
[0016] The magnetic particles are not particularly limited and can be appropriately selected depending on the purpose, and known magnetic particles such as oval or spherical particles formed of a ferromagnetic material can be used, but spherical particles with a particle size of 0.1 μm to 10 μm are preferred. If the particle size is less than 0.1 μm, it may be difficult for the magnet to attract the particles against Brownian motion in the liquid, while if it exceeds 10 μm, the total surface area of the dispersed particle group per unit area may become small, resulting in a decrease in the efficiency of capturing the sialic acid.
[0017] The boronic acid group is a group that selectively binds to the sialic acid from among many sugars in biological materials, and is disposed for the purpose of capturing the sialic acid in biological fluids. In this specification, unless otherwise specified, the term "sialic acid" includes not only sialic acid compounds, which are substances in which the amino group or hydroxy group of neuraminic acid is substituted, but also glycoproteins in which the sialic acid compound is bound to a functionalized sialic acid group, and cells, extracellular vesicles, etc. containing such glycoproteins.
[0018] The boronic acid group (B(OH) 2 R-) has a binding constant K a is 500M -1 As long as the binding constant K is equal to or greater than the above, it can be appropriately selected from among those having any functional group (R-). a is 500M -1 If the concentration is less than this, it is difficult to collect the cells and free proteins having the sialic acid.
[0019] The functional group (R-) has a bonding group to the sialic acid and a bonding group to the linker. The bonding group to the sialic acid is not particularly limited and includes, for example, an alkyl group, an aryl group, a nitrogen-containing heterocyclic group, etc., and these groups may further have any substituent. The bonding group to the linker is also not particularly limited and includes, for example, any divalent linking group that forms any of an ester bond, an ether bond, an amide bond, a urethane bond, and a sulfide bond with the linker.
[0020] The nitrogen-containing heterocyclic group forms a hydrogen bond with the carboxyl group of the sialic acid via the unshared electron pair of the nitrogen atom in the ring, and has a high binding constant K aIt is known that this gives rise to the following (see Non-Patent Document 5). Examples of the nitrogen-containing heterocyclic group include monocyclic groups such as a pyridyl group and a pyrimidinyl group; bicyclic groups such as an indolyl group, an indolinyl group, a quinolinyl group, an isoquinolinyl group, a quinazolinyl group, a quinoxalinyl group, a naphthyridinyl group, a pteridinyl group, and a purinyl group; and fused polycyclic groups such as tricyclic groups such as an acridinyl group, a carbazolyl group, a phenanthridinyl group, a phenazinyl group, and a benzoisoquinolinyl group. When the nitrogen atom in these nitrogen-containing heterocyclic groups is ionized to form a quaternary nitrogen cation, the nitrogen atom that forms a hydrogen bond with the sialic acid loses an unshared electron pair, and is therefore considered to be tertiary. The nitrogen-containing heterocyclic group has a structure in which a hydrogen atom at any position is substituted with a group (e.g., a hydroxyl group or an amino group, which gives a divalent linking group such as —NH— upon dehydration condensation) that forms any one of an ester bond, an ether bond, an amide bond, a urethane bond, and a sulfide bond with the linker.
[0021] Suitable boronic acid groups include those represented by the following chemical structural formula (B a 1) and (B a 2) and 3).
[0022] However, the chemical structural formula (B a 1) Medium, R 1 ~R 4 represents a divalent linking group that forms an ester bond, an ether bond, an amide bond, a urethane bond, or a sulfide bond with the linker, and the remaining groups each independently represent a hydrogen atom or an alkyl group having 1 to 2 carbon atoms. a 2) Medium, R 5 ~R 7 represents a divalent linking group that forms, with the linker, any one of an ester bond, an ether bond, an amide bond, a urethane bond, and a sulfide bond, and the remainders each independently represent a hydrogen atom or an alkyl group having 1 to 2 carbon atoms.
[0023] Among them, the compound represented by the chemical structural formula (B a 1), R 2 is a carboxyl group, and R1 , R 3 , R 4 5-boronopicolinic acid, in which 5-boronopicolinic acid is a hydrogen atom, has a high binding constant K of more than 1,000 with the sialic acid. a It has.
[0024] When the alkyl group or the aryl group is selected as the binding group to the sialic acid, it is preferable that the alkyl group or the aryl group has a structure substituted with a group having an unshared electron pair that forms a hydrogen bond with the sialic acid (for example, -O-, ═O, -N, a hydroxyl group, a carbonyl group, an amino group, etc.). a is given.
[0025] The linker serves to bond the magnetic particle to the boronic acid group, and is therefore designed to have a mechanism for bonding to the magnetic particle and a mechanism for bonding to the boronic acid group.
[0026] The bonding mechanism with the magnetic particles is not particularly limited, but examples thereof include a bonding mechanism using amino groups that have been surface-modified on the magnetic particles.The compound that provides the amino groups on the surface of the magnetic particles is not particularly limited, and may be an amine or an amine derivative.
[0027] The bonding mechanism with the boronic acid group is not particularly limited, but a mechanism that forms any one of an ester bond, an ether bond, an amide bond, a urethane bond, and a sulfide bond with the boronic acid group is preferred in terms of bond stability. Furthermore, the bonding mechanism with the boronic acid group via these bonds is preferably composed of a compound terminated with a thiol group, since this easily provides a functional surface to the magnetic particle. Therefore, the bonding mechanism with the boronic acid group is preferably a mechanism that uses a thiol compound derivative having a functional group (e.g., an amino group or a hydroxyl group) that bonds with the boronic acid group and the thiol group.
[0028] The linker-forming base material is not particularly limited, but includes a link core member that connects the binding mechanism with the magnetic particle and the binding mechanism with the boronic acid group. For example, when the amino group surface-modified on the magnetic particle is selected as the binding mechanism with the magnetic particle and the thiol compound derivative is selected as the binding mechanism with the boronic acid group, the link core member can be composed of a heterobifunctional compound having the N-hydroxysuccinimide ester (NHS ester) and the maleimide group, since the amino group easily reacts with the N-hydroxysuccinimide ester to form a stable amide bond, which is easy to handle, and the thiol group of the thiol compound derivative easily bonds with the maleimide group. Note that, in this specification, the term "linker-forming base material" refers to the linker chemically bonded to the boronic acid group and the magnetic particle, and refers to the linker-forming material in the stage prior to forming the chemical bond between the boronic acid group and the magnetic particle.
[0029] The heterobifunctional compound is not particularly limited, but succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylic acid (SMCC), which is a crosslinker having both the N-hydroxysuccinimide group ester and the maleimide group, and derivatives thereof are preferred because they are easily soluble in water and provide a strong link.
[0030] From the above, it is preferable that the linker forming base material is composed of the amino group that is surface-modified on the magnetic particle, the thiol compound derivative that is bonded to the boronic acid group, and a link core member that has an amide bond that is amide-bonded to the amino group and the maleimide group that is bonded to the thiol group of the thiol compound derivative.
[0031] Furthermore, the linker is not particularly limited, but it is preferable that the linker has an intermediate portion that modifies the surface properties of the magnetic particles in order to suppress non-specific adsorption of contaminants and the like to the magnetic particle surface.
[0032] From the viewpoint of effectively suppressing nonspecific adsorption of the impurities and the like, the intermediate portion is preferably composed of a polymer chain of a homopolymer or copolymer of a monomer selected from the group consisting of ethylene glycol, 2-methoxyacrylate, 2-methacryloyloxyethyl phosphorylcholine, and 3-[[2-(methacryloyloxy)ethyl]dimethylammonio]propionate.
[0033] The mass average molecular weight of the polymer chain is not particularly limited, but is preferably 2,000 to 10,000. If the mass average molecular weight is less than 2,000, it may be difficult to suppress nonspecific adsorption of the impurities, etc., whereas if it exceeds 10,000, steric hindrance of the polymer chain may decrease the number of boronic acid groups bound to the magnetic particles via the linker per unit area, thereby reducing the ability to capture sialic acid.
[0034] The method for introducing the intermediate moiety is not particularly limited, and can be introduced by a known method. When the thiol compound derivative is used, it can be introduced as an intermediate chain of a polymer compound, one end of which is terminated with a functional group (e.g., an amino group or a hydroxyl group) with the boronic acid group, and the other end of which is terminated with the thiol group (for example, -NH-PEG-S- formed using NH-PEG-SH (where PEG means polyethylene glycol chain; the same applies hereinafter) as a base material).
[0035] The above-described binding mechanism with the magnetic particles, the binding mechanism with the boronic acid group, the link core member, and the intermediate portion can each be formed using known forming materials and forming reagents, and although the linker has a novel structure, it can be formed by referring to known reaction procedures for each portion.
[0036] (Method for capturing sialic acid) The method for capturing sialic acid of the present invention includes at least a binding step, a recovery step, and a dissociation step. Hereinafter, the method will be described with reference to the drawings.
[0037] The method for capturing sialic acid uses the complex of the present invention. The complex is shown schematically in Figure 1. In the figure, reference numeral 1 denotes the complex.
[0038] As shown in Figure 2, the binding step is carried out by adjusting the pH of a liquid sample containing complex 1 and a biological fluid containing sialic acid (sialic acid protein 2, etc.) to less than 6, and binding the sialic acid (sialic acid protein 2, etc.) to complex 1. Figure 2 is an explanatory diagram showing an overview of the binding step.
[0039] The sialic acid (such as sialic acid protein 2) binds to the boronic acid group of complex 1 with selectivity for certain pH conditions. The pH condition is less than 6, preferably about 4 to 5.9. An example of a method for adjusting the pH of the liquid sample to less than 6 is to add an acidic solution such as an acetate buffer solution until the target pH is obtained. This adjustment method also includes the dispersion operation itself, such as when the pH of the sample liquid in which complex 1 is dispersed is initially less than 6. The biological fluid is not particularly limited, and examples include blood and urine. However, blood is used when applying to metastatic cancer testing.
[0040] The recovery step is a step of separating and recovering the complex 1 from the liquid sample after the binding step using a magnet. The recovery method is not particularly limited, and examples thereof include a method of bringing a permanent magnet close to a container of the liquid sample to attract the complex 1 to the wall of the container and then disposing of the liquid in the container, and a method of using an electromagnet placed near the container to attract the complex 1 to the wall of the container and then disposing of the liquid in the container.
[0041] As shown in Figure 3, the dissociation step is a step of dissociating the sialic acid (sialic acid protein 2, etc.) from the complex 1 after the recovery step in a concentration solution adjusted to a pH of 7 or higher. Figure 3 is an explanatory diagram showing an overview of the dissociation step.
[0042] As will be described in the Examples below, even after the sialic acid (such as sialic acid protein 2) has formed a strong bond with Complex 1 in the binding step, the bond with the boronic acid group of Complex 1 is released selectively depending on the pH conditions, and the sialic acid is dissociated from Complex 1. The pH condition is 7 or higher, preferably about 7 to 9. An example of a method for adjusting the pH of the concentrating solution to 7 or higher is to add an alkaline solution, such as a phosphate buffer solution adjusted to alkaline, until the desired pH is obtained.
[0043] The concentrated solution of sialic acid obtained after the dissociation step can be used as a test sample for cancer testing. Therefore, the method for capturing sialic acid can utilize the properties of sialic acid related to metastatic cancer to realize comprehensive cancer testing regardless of cancer type, including early-stage cancer.
[0044] As shown in Figure 2, during the binding step, some sialic acid (e.g., sialic acid protein 2) may not bind to complex 1 due to its location away from complex 1. On the other hand, as described in the Examples below, complex 1 maintains its ability to bind and dissociate with sialic acid under pH conditions even after undergoing the series of steps of the binding step, recovery step, and dissociation step. Therefore, complex 1 can bind and dissociate sialic acid even in the second or subsequent binding and dissociation steps when reused. Therefore, after performing the first series of steps on the same biological fluid, the used complex 1 can be reused for the second or subsequent series of steps, thereby improving convenience. Furthermore, the biological fluid does not need to be the same; the series of steps may be performed on different biological fluids collected from the same patient at different times or different body locations. Even in this case, complex 1 used in the series of steps for the first biological fluid can be reused for the series of steps for the second or subsequent biological fluids, thereby improving convenience. That is, as a method for capturing sialic acid, the binding step, the recovery step, and the dissociation step can be carried out by reusing the complex 1 that has undergone the binding step, the recovery step, and the dissociation step for the same or different biological fluids.
[0045] (Example 1; Production of Conjugate) A conjugate compound of boronic acid and a thiol compound derivative was obtained according to the synthesis scheme shown in Figure 4. Specifically, the following operations were carried out.
[0046] First, 33.6 mg (0.2 mmol) of 5-boronopicolinic acid (5-BPA, manufactured by Combi-Blocks) and 12.5 mL of N,N-dimethylformamide (DMF, manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) were placed in a recovery flask, and then ultrasonic treatment was performed to obtain a solution.
[0047] Next, 175 μL of triethylamine (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) and 84 mg (0.025 mmol) of polyethylene glycol (NH-PEG-SH, mass average molecular weight: 3,400, manufactured by Biopharma PEG Scientific Inc.) having an amino group at one end and a thiol group at the other end were placed in a recovery flask, followed by ultrasonic treatment and subsequent stirring to obtain a solution.
[0048] Next, 18.2 mg (0.055 mmol) of 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methyl-morpholinium chloride (DMT-MM, Fujifilm Wako Pure Chemical Industries, Ltd.) was added as a triazine-based condensing agent to the recovery flask, and the mixture was stirred for 4 hours to obtain the reaction product of 5-BPA and NH-PEG-SH (BPEG-disulfide).
[0049] Next, the solution was dialyzed (molecular weight cutoff: 3,500) with a 5M aqueous sodium hydroxide solution (Fujifilm Wako Pure Chemical Industries, Ltd.) diluted to 100 mM to exchange the solution from DMF and remove unreacted 5-BPA. The dialyzed solution was then stirred for approximately 12 hours. The same dialysis was repeated twice to thoroughly remove unreacted 5-BPA. The solution was then dialyzed with pure water to exchange the solution, followed by freeze-drying to remove water, yielding a dry solid of BPEG-disulfide.
[0050] The resulting BPEG-disulfide was in a disulfide state, where the thiol terminus was oxidized and bonded, and was then reduced to a thiol molecule using tris(2-carboxyethyl)phosphine hydrochloride (TCEP-HCl, Fujifilm Wako Pure Chemical Industries, Ltd.) as a reducing agent to obtain a bonded compound (BPEG-SH) of boronic acid and a thiol compound derivative. This reduction treatment was carried out immediately before bonding with magnetic particles, as described below.
[0051] A complex in which a boronic acid group was conjugated to a magnetic particle via a linker was prepared according to the preparation scheme shown in Figure 5. Specifically, the following operations were carried out.
[0052] First, 5 mg of succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylic acid (SMCC, manufactured by ProteoChem) serving as the link core member was dissolved in 100 μL of DMF.
[0053] Next, 1 μm Sera-Mag TM 1 mL of SpeedBead Blocked Amino Particles (manufactured by Global Life Sciences Solutions Operations UK Ltd. (Cytiva), containing azide) was placed in an Eppendorf tube, and a magnet was used to attract the magnetic particles to the side of the Eppendorf tube. A pipette was then inserted into the Eppendorf tube and the azide was removed by pipetting. Washing was then performed twice with pure water to obtain a dispersion of magnetic particles dispersed in 1 mL of pure water. The magnetic particles were spherical particles with a particle size of 1 μm and surface-modified with amino groups.
[0054] Next, the DMF solution of SMCC and the aqueous dispersion of magnetic particles were mixed and stirred for 1 hour. After the reaction, the magnetic particles were washed with pure water to remove unreacted SMCC. This yielded magnetic particles surface-treated with SMCC.
[0055] Next, 9.2 mg of the BPEG-disulfide obtained above was dissolved in 1 mL of purified water to prepare a 2.6 mM BPEG solution. Also, 100 μL of a 200 mM aqueous solution of TCEP-HCl (Mw: 286.65, 57.4 mg / mL, Fujifilm Wako Pure Chemical Industries, Ltd.) was prepared. The TCEP (hydrochloric acid solution) and the BPEG solution were mixed and reacted for 1 hour to obtain the BPEG-SH solution described above (see Figure 4).
[0056] Next, the magnetic particles surface-treated with SMCC were added to the BPEG-SH solution and reacted for 1 hour in a tube shaker, resulting in a dispersion containing a reaction product (complex related to Example 1) in which boronic acid groups were immobilized on the surface of the magnetic particles via a linker through a thioetherification reaction between the maleimide group of SMCC and the thiol group of BPEG-SH.
[0057] (Example 2: Selective binding of sialic acid depending on pH conditions) First, as an example, fetuin (manufactured by Merck (Sigma-Aldrich)), a protein having a high density of sialic acid, was prepared as a model of sialic acid. Next, fetuin was dissolved in 10 mM acetate buffer solution at pH 5.0 to prepare a 1 mg / mL fetuin aqueous solution. 1 mL of the fetuin aqueous solution and 64 μL of the dispersion of the complex according to Example 1 were placed in an Eppendorf tube and mixed to bind the fetuin and the complex (binding step). In the following, fetuin, a protein having a high density of sialic acid, will be referred to simply as "sialic acid" for convenience. However, Figures 6 to 8, which will be explained later, are figures showing the results of measurement or analysis of the amount or number of fetuin itself using a "sialic acid quantification kit." To avoid misunderstanding that these are the results of measurement or analysis of the amount or number of sialic acid itself liberated from fetuin by an enzyme, the abbreviation "sialic acid" will be avoided in the graphs of Figures 6 to 8, and the term "fetuin" (a protein having a high density of sialic acid) will be used faithfully. Furthermore, in the explanation of Figures 6 to 8, it will be clearly stated that "sialic acid" refers to "fetuin."
[0058] Next, a magnet was used to attract the magnetic particles to the side of the Eppendorf tube, and a pipette was inserted into the Eppendorf tube to remove unreacted sialic acid by suction. The complex after the binding step was then washed twice with 1 mL of 10 mM acetate buffer. The 10 mM acetate buffer solution in the Eppendorf tube was then similarly removed by pipetting (recovery step).
[0059] Next, 50 μL of 10 mM phosphate buffer solution (pH 7.6) was added to the Eppendorf tube containing the complex bound to sialic acid, and the tube was shaken and stirred to dissociate the complex from the sialic acid (dissociation step). In this way, the method for capturing sialic acid according to Example 2 was carried out.
[0060] Next, with the magnetic particles attracted to the wall of the Eppendorf tube using a magnet, the amount of dissociated sialic acid in the 10 mM phosphate buffer solution was quantified using a sialic acid quantification kit (Agilent AdvanceBio Total Sialic Acid Quantitation Kit, manufactured by Agilent Technologies).
[0061] This quantitative test was carried out on a total of five samples, in which the amount of the complex dispersion was changed to 16 μL, 4 μL, 2 μL, and 1 μL in addition to the previously described 64 μL.
[0062] For comparison, a comparative test was conducted in which the same amount of 10 mM phosphate buffer was used instead of the 10 mM acetate buffer, and the pH was kept at 7.6 throughout the test. This comparative test was also conducted on a total of five samples, with the amounts of the composite dispersion varied between 64 μL, 16 μL, 4 μL, 2 μL, and 1 μL.
[0063] The results of the quantitative test for sialic acid (denoted as "fetuin" in the figure) are shown in Figure 6(a). As shown in Figure 6(a), in the (1) quantitative test using a 10 mM acetate buffer solution at a pH of 5.0, the amount of quantified sialic acid increased with an increase in the amount of complex dispersion, demonstrating that sialic acid was successfully bound to the complex of Example 1. That is, even when a complex is formed using magnetic particles and a linker added to the magnetic particles for surface treatment of the boronic acid groups, the binding reaction between the boronic acid groups and sialic acid can proceed. The capture of sialic acid by the complex of Example 1 is dependent on the pH, as it was not confirmed in a comparative test conducted at a pH of 7.6.
[0064] Furthermore, (2) sialic acid that is not dissociated from the complex is not detected in the quantitative test, which indicates that the sialic acid that was once bound to the complex of Example 1 in the binding step under pH conditions of 5.0 can be dissociated from the complex by carrying out the dissociation step under pH conditions of 7.6. In other words, the selective binding property depending on the pH conditions is effective not only when sialic acid is bound to the complex but also when sialic acid bound to the complex is dissociated, and sialic acid can be bound to the complex with a high binding constant (Ka ) can be subsequently dissociated from the complex by controlling the pH conditions, and free sialic acid can be stably obtained.
[0065] Furthermore, Figure 6(b) shows the results of analysis of the number of dissociated sialic acids (indicated as "fetuin number" in the figure) in the quantitative test (pH 5.0) and the comparative test (pH 7.6) using a sample with a complex dispersion volume of 64 µL. As shown in Figure 6(b), the quantitative test (pH 5.0) confirmed dissociation of sialic acid with a significant difference compared to the comparative test (pH 7.6). In other words, the effectiveness of pH control in binding sialic acid in the binding step and dissociation of sialic acid in the dissociation step is strongly supported.
[0066] (Example 3: Reusability test of conjugate) The binding step, recovery step, and dissociation step were carried out in the same manner as in the method for capturing sialic acid in Example 2, except that the amount of dispersion of the conjugate in Example 1 was only 64 μL. This series of steps, including the binding step, recovery step, and dissociation step, is referred to as the first step.
[0067] After the dissociation step, a pipette was inserted into the Eppendorf tube while the magnetic particles were attracted to the wall of the Eppendorf tube using a magnet, and the sialic acid dissociation solution was pipetted and recovered. Subsequently, a 1 mg / mL aqueous solution of sialic acid (the fetuin aqueous solution in Example 2; the same applies below) was added as new sialic acid to the Eppendorf tube containing the remaining magnetic particles, and a 10 mM acetate buffer solution was added to adjust the pH to 5.0, to carry out the binding step. Subsequently, the same recovery and dissociation steps as in the sialic acid collection method of Example 2 were carried out. This series of binding, recovery, and dissociation steps was designated the second step, and the same series of binding, recovery, and dissociation steps was repeated three times with the same content as in the second step. These repeated steps were designated the third to fifth steps, respectively. In this manner, the sialic acid collection method of Example 3 was carried out. In the method for capturing sialic acid according to Example 3, the complex used in the first step was reused in the subsequent second to fifth steps, and was subjected to the binding and dissociation procedures with sialic acid five times each.
[0068] The dissociated sialic acid solutions collected from each of the first to fifth steps were subjected to the same quantitative test as in Example 2. The results of the quantitative test of sialic acid (shown as "fetuin" in the figure) regarding the reuse of the complex are shown in Figure 7. As shown in Figure 7, the amount of sialic acid obtained remained at 80% or more of that obtained in the first step even in the fifth step, confirming the high reusability of the complex.
[0069] In actual cancer testing, it is expected that the amount of sialic acid contained in a biological fluid may be extremely small. In a single test, due to the detection limit of concentration, sialic acid may not be detected due to unreacted sialic acid with the conjugate. In this case, it is possible to perform multiple tests on the same biological fluid, but there is a significant difference in convenience between starting with the conjugate manufacturing process described in Example 1 for each test and simply reusing the conjugate used in the first test. Furthermore, when performing simultaneous tests on different biological fluids collected from the same patient at different times or different body locations, there is a significant difference in convenience between performing the conjugate manufacturing process described in Example 1 for each collected biological fluid and simply reusing the conjugate used in the first test. The high reusability of the conjugate, as confirmed by Figure 7, provides excellent practical convenience.
[0070] (Example 4: Sialic Acid Concentration Test) The binding step, recovery step, and dissociation step were carried out in the same manner as in the sialic acid collection method of Example 2, except that the sialic acid concentration of the sialic acid aqueous solution was changed from 1 mg / mL to 10 μg / mL, the volume of the sialic acid aqueous solution was changed from 1 mL to 10 mL, and the volume of the dispersion of the complex of Example 1 was only 64 μL. Next, after the dissociation step, a magnet was used to attract the magnetic particles to the bottom of the Eppendorf tube, and the supernatant was removed to recover the dissociated sialic acid solution. The recovered dissociated sialic acid solution was subjected to a quantitative test similar to that of Example 2. This test is referred to as Concentration Test 1 (sialic acid concentration: 10 μg / mL).
[0071] A quantitative test for a dissociated solution of sialic acid was also conducted in the same manner as in Concentration Test 1, except that the sialic acid concentration of the aqueous sialic acid solution was changed from 10 μg / mL to 1 μg / mL and the volume of the aqueous sialic acid solution was changed from 10 mL to 100 mL. This test is designated Concentration Test 2 (sialic acid concentration: 1 μg / L).
[0072] The test results for Concentration Test 1 are shown in Figure 8(a). The test results for Concentration Test 2 are shown in Figure 8(b). Note that in these figures, the term "fetuin" is used faithfully, rather than referring to sialic acid. As shown in Figures 8(a) and (b), in both Concentration Tests 1 and 2, the concentration of sialic acid in the sialic acid dissociation solution was approximately 21 times higher than the concentration in the initial sialic acid aqueous solution, demonstrating that sialic acid could be significantly concentrated. Use of this concentrated solution can significantly improve the detection performance of cancer tests that use sialic acid.
[0073] 1 Complex 2 Sialic acid protein
Claims
1. A complex represented by the following formula (1): a -L-M p (1) In the above formula (1), B a is the binding constant K a is 500M -1 represents a boronic acid group or more; M p represents a magnetic particle having ferromagnetic properties, L represents a linker that bonds the boronic acid group and the magnetic particle, and the complex represented by formula (1) represents a state in which the boronic acid group and the magnetic particle are chemically bonded via the linker.
2. The composite according to claim 1, wherein the magnetic particles are spherical particles having a diameter of 0.1 μm to 10 μm.
3. The boronic acid group has the following chemical structure (B a 1) and (B a 3. The complex according to claim 1 or 2, wherein said complex is represented by any one of the following formulas: However, the above-mentioned chemical structural formula (B a 1) Medium, R 1 ~R 4 Any one of the above represents a divalent linking group that forms an ester bond, an ether bond, an amide bond, a urethane bond, or a sulfide bond with the linker, and the remaining groups each independently represent a hydrogen atom or an alkyl group having 1 to 2 carbon atoms. a 2) Medium, R 5 ~R 7 represents a divalent linking group that forms any one of an ester bond, an ether bond, an amide bond, a urethane bond, and a sulfide bond with the linker, and the remainders each independently represent a hydrogen atom or an alkyl group having 1 to 2 carbon atoms.
4. The complex described in claim 1 or 2, wherein the linker forming base material comprises an amino group that is surface-modified onto the magnetic particle, a thiol compound derivative that is bonded to a boronic acid group, and a link core member having an amide bond that is amide-bonded to the amino group and a maleimide group that is bonded to the thiol group of the thiol compound derivative.
5. The conjugate of claim 4, wherein the link core member is a heterobifunctional compound having an N-hydroxysuccinimide ester group and a maleimide group.
6. The complex of claim 1 or 2, wherein the linker has an intermediate moiety which modifies the surface properties of the magnetic particle.
7. The complex of claim 6, wherein the intermediate portion is composed of a polymer chain of a homopolymer or copolymer of a monomer selected from the group consisting of ethylene glycol, 2-methoxyacrylate, 2-methacryloyloxyethyl phosphorylcholine, and 3-[[2-(methacryloyloxy)ethyl]dimethylammonio]propionate.
8. The complex according to claim 7, wherein the mass average molecular weight of the polymer chain is 2,000 to 10,000.
9. A method for capturing sialic acid, comprising the steps of: adjusting the pH of a liquid sample containing the complex according to claim 1 or 2 and a biological fluid containing sialic acid to less than 6, and binding the sialic acid to the complex; recovering the complex after the binding step by using a magnet to separate it from the liquid sample and recover it; and dissociating the sialic acid from the complex after the recovery step in a concentration liquid adjusted to a pH of 7 or higher.
10. A method for capturing sialic acid as described in claim 9, in which the complex that has been subjected to the binding, recovery and dissociation steps is reused to carry out the binding, recovery and dissociation steps on the same or a different biological fluid.
Citation Information
Patent Citations
Heterocyclic boronic acid derivative
WO2019004482A1
